Skip to main content
. Author manuscript; available in PMC: 2017 Apr 20.
Published in final edited form as: Nature. 2017 Jan 18;542(7639):119–123. doi: 10.1038/nature21052

Figure 1. ME2 is a passenger deletion in patients with PDAC.

Figure 1

a, Interactive genome viewer (IGV) image of chromosome 18 encompassing region q21 of PDAC cell lines from CCLE data set. Twelve of 46 PDAC samples had homozygous deletion of ME2. b, Ideogram of chromosome 18 showing close proximity (<200 kb) of ME2 to SMAD4. c, Correlation of copy-number alterations (CNA) between SMAD4 and ME2 in PDAC samples. d, ME2 deletion events in PDAC samples (TCGA) showing a correlation between CNA and mRNA expression. Homozygous deletion in 16 of 185 samples. e, Frequency of ME2 and SMAD4 deletion in multiple solid tumours (cBioportal). Boxes detail ME2 and SMAD4 deletion frequency from UTSW and TCGA PDAC datasets. adeno, adenocarcinoma; DLBC, Diffuse large B-cell lymphoma; MPNST, Malignant Peripheral Nerve Sheath Tumors; NEPC, Neuroedocrine prostate cancer.